The GLP-1 receptor agonists are generally recommended as a second or third-line option as add-on to metformin therapy in patients with T2DM who do not have ASCVD/indicators of high-risk for ASCVD, HF, or CKD and who need to minimize hypoglycemia and/or promote weight loss
GLP-1s are known to have positive cardiovascular effects, and better control of blood glucose levels through GLP-1 treatment has been shown to limit small blood vessel damage that can lead to health complications such as diabetic retinopathy
By activating GLP-1, protecting against oxidative stress, and boosting both physical and mental energy, it paves the way for sustainable transformation
Therapeutic Research Protocol Dose: 0.5 0.9 mg (= 1018 clicks) Duration: 3 4 weeks Frequency: 2 daily, divided doses Cycle Interval: 4 weeks off before repeating Goal / Description: Higher-dose protocol used in stress-response and GABAergic modulation studies
Can IV therapy be combined with other treatments
